Major Customers, Partnerships and Strategic Alliances (Tables)

Revenues recognized under the agreement for the three and nine months ended September 30, 2018 were as follows (in thousands):

	September 30, 2018
	Three Months Ended		Nine Months Ended
Revenue related to Kite Collaboration:
Recognition of upfront fee	$	6,296	$	12,249
Research services		2,732		4,295
Total	$	9,028	$	16,544

Revenues recognized under the agreement for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Revenue related to Pfizer Collaboration for SB-525:
Recognition of upfront fee	$	10,421	$	6,624	$	26,262	$	10,384

Revenues recognized under the agreement for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Revenue related to Bioverativ agreement:
Recognition of upfront fee	$	1,094	$	442	$	3,432	$	1,326
Research services		1,146		2,959		7,707		7,736
Total	$	2,240	$	3,401	$	11,139	$	9,062

Revenues recognized under the agreement for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Revenue related to Shire agreement:
Recognition of upfront fee	$	—	$	1,166	$	—	$	2,333
Research services		—		6		—		116
Total	$	—	$	1,172	$	—	$	2,449